OFIX Valuation

Orthofix Medical Inc

Add to Watchlist

Advanced Chart

14.230

+0.21(1.498%)1D

Overview
Forecast
Valuation
Earnings

OFIX Relative Valuation

OFIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OFIX is overvalued; if below, it's undervalued.

Historical Valuation

Orthofix Medical Inc (OFIX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.66 is considered Undervalued compared with the five-year average of -4.18. The fair price of Orthofix Medical Inc (OFIX) is between 18.54 to 33.34 according to relative valuation methord. Compared to the current price of 14.23 USD , Orthofix Medical Inc is Undervalued By 23.24%.

Relative Value

Fair Zone

18.54-33.34

Current Price：14.23

23.24%

Undervalued

-8.47

Trailing

Forward

7.88

EV/EBITDA

Orthofix Medical Inc. (OFIX) has a current EV/EBITDA of 7.88. The 5-year average EV/EBITDA is 10.21. The thresholds are as follows: Strongly Undervalued below 4.39, Undervalued between 4.39 and 7.30, Fairly Valued between 13.12 and 7.30, Overvalued between 13.12 and 16.03, and Strongly Overvalued above 16.03. The current Forward EV/EBITDA of 7.88 falls within the Historic Trend Line -Fairly Valued range.

-13.16

EV/EBIT

Orthofix Medical Inc. (OFIX) has a current EV/EBIT of -13.16. The 5-year average EV/EBIT is -552.76. The thresholds are as follows: Strongly Undervalued below -5302.72, Undervalued between -5302.72 and -2927.74, Fairly Valued between 1822.22 and -2927.74, Overvalued between 1822.22 and 4197.20, and Strongly Overvalued above 4197.20. The current Forward EV/EBIT of -13.16 falls within the Historic Trend Line -Fairly Valued range.

0.66

Orthofix Medical Inc. (OFIX) has a current PS of 0.66. The 5-year average PS is 1.03. The thresholds are as follows: Strongly Undervalued below 0.17, Undervalued between 0.17 and 0.60, Fairly Valued between 1.46 and 0.60, Overvalued between 1.46 and 1.89, and Strongly Overvalued above 1.89. The current Forward PS of 0.66 falls within the Historic Trend Line -Fairly Valued range.

6.89

P/OCF

Orthofix Medical Inc. (OFIX) has a current P/OCF of 6.89. The 5-year average P/OCF is 19.61. The thresholds are as follows: Strongly Undervalued below -34.59, Undervalued between -34.59 and -7.49, Fairly Valued between 46.71 and -7.49, Overvalued between 46.71 and 73.81, and Strongly Overvalued above 73.81. The current Forward P/OCF of 6.89 falls within the Historic Trend Line -Fairly Valued range.

84.74

P/FCF

Orthofix Medical Inc. (OFIX) has a current P/FCF of 84.74. The 5-year average P/FCF is -485.45. The thresholds are as follows: Strongly Undervalued below -4588.81, Undervalued between -4588.81 and -2537.13, Fairly Valued between 1566.24 and -2537.13, Overvalued between 1566.24 and 3617.92, and Strongly Overvalued above 3617.92. The current Forward P/FCF of 84.74 falls within the Historic Trend Line -Fairly Valued range.

Orthofix Medical Inc (OFIX) has a current Price-to-Book (P/B) ratio of 1.23. Compared to its 3-year average P/B ratio of 1.04 , the current P/B ratio is approximately 17.31% higher. Relative to its 5-year average P/B ratio of 1.42, the current P/B ratio is about -13.70% higher. Orthofix Medical Inc (OFIX) has a Forward Free Cash Flow (FCF) yield of approximately 0.08%. Compared to its 3-year average FCF yield of -9.96%, the current FCF yield is approximately -100.84% lower. Relative to its 5-year average FCF yield of -4.81% , the current FCF yield is about -101.73% lower.

1.23

P/B

Median3y

1.04

Median5y

1.42

0.08

FCF Yield

Median3y

-9.96

Median5y

-4.81

Competitors Valuation Multiple

The average P/S ratio for OFIX's competitors is 1.65, providing a benchmark for relative valuation. Orthofix Medical Inc Corp (OFIX) exhibits a P/S ratio of 0.66, which is -59.79% above the industry average. Given its robust revenue growth of 2.27%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Castle Biosciences Inc

Organogenesis Holdings Inc

1.04

-22.44%

600.04M

Performance Decomposition

Market capitalization of OFIX decreased by 18.41% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -3.24 to -4.47.

The secondary factor is the Revenue Growth, contributed 2.27%to the performance.

Overall, the performance of OFIX in the past 1 year is driven by P/E Change. Which is more unsustainable.

2.27%

198.62M → 203.12M

Revenue Growth

-58.85%

-16.84 → -6.93

Margin Expansion

38.17%

-3.24 → -4.47

P/E Change

-18.41%